← Back to Search

E-health Applications for Dementia (TNCM Trial)

N/A
Recruiting
Research Sponsored by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be 65 years old or older
Understand French or English orally and in writing. The speakers are French and/or English speaking, and the questionnaires are only available in these 2 languages.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 months
Awards & highlights

TNCM Trial Summary

This trial will help assess whether two health applications, CARE© and ESOGER©, can help improve the care pathway for people living with major neurocognitive disorders.

Who is the study for?
This trial is for individuals aged 65 or older with major neurocognitive disorders (MNCD) who have caregivers and live at home or in non-medicalized senior residences in Montreal. Participants must have internet access, a digital device, and understand French or English.Check my eligibility
What is being tested?
The study tests two e-health applications: CARE©, a self-assessment for frailty completed by the patient-caregiver dyad; and ESOGER©, an evaluation filled out by a worker to help prioritize care needs. The goal is to improve physical/mental health and quality of life while reducing hospital visits.See study design
What are the potential side effects?
Since this trial involves questionnaires and recommendations rather than medical treatments, traditional side effects are not expected. However, participants may experience discomfort discussing personal health issues during assessments.

TNCM Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 65 years old or older.
Select...
I can understand and communicate in either French or English.
Select...
I have been diagnosed with a major neurocognitive disorder.

TNCM Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
CARE© Score
Response Rate to CARE© questionnaires
Secondary outcome measures
BGA Score
COVID-19 symptoms
Caregiver burden
+7 more

TNCM Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention groupExperimental Treatment1 Intervention
Phase 1 Participants will assess their health status, at home, at recruitment (M0) and at 3 months (M3) with CARE© with the help of their family caregivers. The principal investigator or a representative will contact them by phone within 5 days of the CARE© assessment to complete ESOGER. Phase 2 Participants will assess their health status, at home, at recruitment (M0), at 3 months (M3), and at 6 months (M6) on the CARE© application with the help of their family caregivers. An additional assessment will take place over the phone by the principal investigator or one of his representatives. If their health status is considered fragile, then individuals will be contacted by phone by the PI or one of his representatives to complete the ESOGER© questionnaire (at M0, M3 and M6).
Group II: Control groupActive Control1 Intervention
Phase 1 Participants will assess their health status, by telephone, at recruitment (M0) and at 3 months (M3) with CARE© with the help of their family caregivers. The principal investigator or a representative will contact them by phone within 5 days of the CARE© assessment to complete ESOGER. Phase 2 Participants will assess their health status, at home, at recruitment (M0), at 3 months (M3), and at 6 months (M6) on the CARE© application with the help of their family caregivers. An additional assessment will take place over the phone by the principal investigator or one of his representatives. If their health status is considered fragile, then individuals will be contacted by phone by the PI or one of his representatives to complete the ESOGER© questionnaire (at M0, M3 and M6).

Find a Location

Who is running the clinical trial?

Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-MontréalLead Sponsor
9 Previous Clinical Trials
4,047 Total Patients Enrolled

Media Library

CARE© Clinical Trial Eligibility Overview. Trial Name: NCT05571553 — N/A
Dementia Research Study Groups: Intervention group, Control group
Dementia Clinical Trial 2023: CARE© Highlights & Side Effects. Trial Name: NCT05571553 — N/A
CARE© 2023 Treatment Timeline for Medical Study. Trial Name: NCT05571553 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies available to partake in the clinical trial?

"According to the clinicaltrials.gov website, this particular trial is no longer seeking participants. Initially posted on October 10th 2022 and last modified on October 6th 2022, it has ceased recruitment. However, there are 561 other studies that are actively looking for individuals at present."

Answered by AI

What are the primary objectives of this clinical experiment?

"The primary goal of this 4-month long clinical trial is to measure the CARE© Score. Additionally, Social Isolation will be gauged through medication access and homecare availability; Quality of Life will be monitored using EuroQol-5D, a questionnaire with 5 questions and an accompanying visual scale running from 0 (worst) to 100 (best); Lastly, Loss of Autonomy shall be evaluated via two scales – Activities of Daily Living (ADL), ranging from 0 (dependent) to 6 (independent), and Instrumental Activities of Daily Living (IADL) which goes from 0 (not autonomous) to 4(autonomous"

Answered by AI
~40 spots leftby Aug 2024